Dermata Therapeutics Secures Australian Patent Acceptance For Bioneedle System In Dermal Fillers

Dermata Therapeutics has received acceptance for its patent application in Australia for the Bioneedle Delivery System (BDS) related to dermal fillers, marking its first patent in this area if issued. The company already holds allowed and issued patents in the US, Australia, and Japan for the use of BDS with botulinum toxin for hyperhidrosis treatment. The patent, titled 'Compositions for the treatment of conditions by dermal fillers,' will be automatically issued in three months unless opposed.